NCT01661179

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Genzyme, a Sanofi Company · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.

Detailed description

A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma

Conditions

• Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma

Interventions

Type	Name	Description
DRUG	Vandetanib 300mg	300 mg oral dose once daily (100 mg x 3 tablets)

Timeline

• Start date: 2012-11-01
• Primary completion: 2013-12-01
• Completion: 2014-07-01
• First posted: 2012-08-09
• Last updated: 2016-12-05
• Results posted: 2015-05-19

Locations

4 sites across 1 country: Japan